What's Happening?
Exelixis, Inc. reported its third-quarter 2026 financial results, with total revenues reaching $658.7 million, an increase from $597.8 million in the comparable period of 2025. Net product revenues, primarily from the cabozantinib franchise, were $604.9
million. The company also provided updates on its zanzalintinib development program, including the ongoing U.S. Food and Drug Administration (FDA) review of its New Drug Application (NDA) for zanzalintinib in combination with atezolizumab for previously treated metastatic colorectal cancer (CRC), with a Prescription Drug User Fee Act (PDUFA) target action date of March 3, 2027. Additionally, Exelixis announced a favorable appellate ruling in its patent lawsuit against MSN Laboratories, upholding the validity of several U.S. patents and delaying the effective date of any final FDA approval of MSN’s Abbreviated New Drug Application (ANDA) until at least January 15, 2030.
Why It's Important?
Exelixis' financial performance and pipeline advancements are significant for the oncology sector. The ongoing FDA review of zanzalintinib for metastatic CRC could introduce a new treatment option for patients with limited alternatives. The patent litigation outcome against MSN Laboratories is crucial for protecting Exelixis' intellectual property and market exclusivity for its cabozantinib franchise, ensuring continued revenue generation from its flagship product. This ruling provides a degree of certainty regarding the competitive landscape for several years, allowing Exelixis to further invest in its research and development efforts and commercialization strategies. The company's focus on disciplined capital deployment, including stock repurchases and evaluating external innovation, reflects a strategic approach to long-term value creation.
What's Next?
Exelixis anticipates topline results from the Phase 3 STELLAR-304 pivotal trial in the first quarter of 2027, evaluating zanzalintinib in advanced non-clear cell renal cell carcinoma. The company is also actively enrolling patients in other pivotal trials, including STELLAR-311 for advanced neuroendocrine tumors and STELLAR-201 for recurrent meningioma, with the latter potentially becoming the first systemic therapy for this condition. The FDA's decision on the zanzalintinib NDA for metastatic CRC is expected by March 3, 2027. Exelixis will continue to manage its patent portfolio and monitor the outcome of separate consolidated litigation with MSN, which has a trial scheduled for November 2026, to safeguard its market position.
